A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379
Status:
Completed
Trial end date:
2021-03-26
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of
JNJ-56136379 in participants with liver cirrhosis and impaired hepatic function when compared
with healthy participants with normal hepatic function and no liver cirrhosis.